These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 2673804)

  • 21. Interleukin 2 receptor-targeted therapy in islet transplantation research.
    Hahn HJ; Kuttler B; Volk HD; Lucke S; Diamantstein T
    Horm Metab Res Suppl; 1990; 25():177-80. PubMed ID: 2088963
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
    Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo.
    Tanaka K; Turka LA; Ueda H; Diamantstein T; Milford EL; Carpenter CB; Tilney NL; Kupiec-Weglinski JW
    Transplant Proc; 1989 Feb; 21(1 Pt 1):475-6. PubMed ID: 2523145
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunosuppression by means of antilymphocyte serums in humans].
    Revillard JP
    Nouv Rev Fr Hematol; 1972; 12(2):129-37. PubMed ID: 4264610
    [No Abstract]   [Full Text] [Related]  

  • 25. Phenotypical characterization of the cells invading pancreatic islets of diabetic BB/OK rats: effect of interleukin 2 receptor-targeted immunotherapy.
    Hahn HJ; Gerdes J; Lucke S; Liepe L; Kauert C; Volk HD; Wacker HH; Brocke S; Stein H; Diamantstein T
    Eur J Immunol; 1988 Dec; 18(12):2037-42. PubMed ID: 3065088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
    Ramos EL; Leggat JE; Milford EL; Kirkman RL; Tilney NL; Strom TB; Shapiro ME; Waldmann TA; Carpenter CB
    Trans Assoc Am Physicians; 1989; 102():231-9. PubMed ID: 2534707
    [No Abstract]   [Full Text] [Related]  

  • 27. Coinjection of anti-interleukin-2 receptor antibody diminishes antiantibody formation during prolonged treatment with anti-CD3 antibody.
    Mysliwietz J; Thierfelder S
    Transplantation; 1993 Nov; 56(5):1266-9. PubMed ID: 8249136
    [No Abstract]   [Full Text] [Related]  

  • 28. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison of the effector mechanisms mediated by variant murine isotypes.
    Stünkel KG; Grützmann R; Diamantstein T; Kupiec-Weglinski JW; Schlumberger HD
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1003-5. PubMed ID: 2784878
    [No Abstract]   [Full Text] [Related]  

  • 31. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
    Waldmann TA
    Nat Rev Immunol; 2006 Aug; 6(8):595-601. PubMed ID: 16868550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.
    Waldmann TA
    Clin Immunol Immunopathol; 1991 Nov; 61(2 Pt 2):S37-46. PubMed ID: 1934612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy through the IL-2 receptor.
    Verheul HA; Verveld M; Bos ES
    Immunol Res; 1992; 11(1):42-53. PubMed ID: 1602182
    [No Abstract]   [Full Text] [Related]  

  • 34. Takeda's second bet on DARTs.
    Nat Biotechnol; 2014 Nov; 32(11):1070. PubMed ID: 25380421
    [No Abstract]   [Full Text] [Related]  

  • 35. [New induction immunosuppression treatments in kidney transplantation].
    Pascual J; Ortuño J
    Med Clin (Barc); 2001 Jun; 117(4):147-57. PubMed ID: 11472688
    [No Abstract]   [Full Text] [Related]  

  • 36. [Should we block interleukin-1 in atherothrombosis?].
    Nicoletti A; Caligiuri G; Ho-Tin-Noé B; Michel JB
    Med Sci (Paris); 2012; 28(6-7):580-2. PubMed ID: 22805131
    [No Abstract]   [Full Text] [Related]  

  • 37. Low-dose interleukin-2 therapy in autoimmune and inflammatory diseases: facts and hopes.
    Li ZG; He J; Miao M
    Sci Bull (Beijing); 2023 Jan; 68(1):10-13. PubMed ID: 36621432
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current status and new trends in therapeutic antibodies].
    Saito M
    Nihon Yakurigaku Zasshi; 2016 Mar; 147(3):168-74. PubMed ID: 26960778
    [No Abstract]   [Full Text] [Related]  

  • 39. Surgical immunology.
    Hamilton DN
    Lancet; 1976 Jan; 1(7952):188-9. PubMed ID: 54694
    [No Abstract]   [Full Text] [Related]  

  • 40. Current stage of interleukin 2 receptor targeted therapy.
    Diamantstein T; Kupiec-Weglinski JW; Strom TB; Tilney NL
    Exp Clin Endocrinol; 1989 May; 93(2-3):114-24. PubMed ID: 2673804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.